FDA Approves Symbravo for Acute Treatment of Migraine in Adults
By Lori Solomon HealthDay Reporter
WEDNESDAY, Feb. 5, 2025 -- The U.S. Food and Drug Administration has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.
The approval was based on the results of three phase 3 trials of more than 21,000 migraine attacks combined. In the MOMENTUM trial, which treated migraine of moderate and severe pain intensity, Symbravo showed a statistically significantly greater percentage of patients achieving pain freedom and freedom from their most bothersome symptom (photophobia, phonophobia, nausea) two hours after dosing versus placebo, with benefits of pain freedom sustained through 24 and 48 hours for many patients. In the INTERCEPT trial, which treated migraine when the initial pain was mild, similar results were seen. Finally, in the MOVEMENT long-term open-label safety trial (706 patients; treating at least two migraines per month), the long-term safety of Symbravo was shown, with the most common adverse events being somnolence and dizziness.
"Migraine attacks strike without warning, and disrupt the lives of estimated more than 39 million patients in the U.S. alone," Herriot Tabuteau, M.D., CEO of Axsome Therapeutics, said in a statement. "Symbravo provides patients and clinicians an important new option which can quickly stop a migraine attack, keep it away, and allow patients to resume their normal activities, with just a single dose."
Approval of Symbravo was granted to Axsome Therapeutics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Too Often, ER Docs Don't Spot Migraines in Minority Kids
THURSDAY, Feb. 6, 2025 -- Kids and teens can also get migraines, but Black and Hispanic children seen in ERs are more likely to have their condition go undiagnosed, new research...
Beta Blocker Propranolol Might Reduce Migraine Stroke Risk
MONDAY, Feb. 3, 2025 -- A common drug used to prevent migraines might have an additional benefit -- protecting women against stroke. Women taking the beta blocker propranolol to...
Quick Fix? New Migraine Medicine, Qulipta, May Start Working Right Away
THURSDAY, Dec. 26, 2024 -- Migraine patients often suffer a long time before docs zero in on the best dosage for drugs designed to prevent their terrible symptoms. But a recently...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.